What you're saying is: instead of posting a hundred messages about Radient appearing or not appearing on a meaningless Delaware search engine, RXPC shareholders should INSTEAD pay $10 and find out the corporate status of Radient Pharmaceuticals.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.